Status:
TERMINATED
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
Lead Sponsor:
Washington University School of Medicine
Conditions:
Autoimmunity
Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy.
Detailed Description
Details will be available upon publication.
Eligibility Criteria
Inclusion
- ≥18 years of age.
- Diagnosis of skin cancer.
- Planning to initiate or already on ANY type of immunotherapy.
- Able to provide urine and stool specimens.
Exclusion
- Bowel resection.
- Major GI surgery in the past 5 years other than cholecystectomy and appendectomy.
Key Trial Info
Start Date :
November 8 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT03370861
Start Date
November 8 2017
End Date
December 31 2022
Last Update
September 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barnes-Jewish Hosptial
St Louis, Missouri, United States, 63110